Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1998-09-16
2000-05-09
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514272, 514912, 514913, A61K 31675, A61K 31505
Patent
active
060604638
ABSTRACT:
Methods for treatment of conditions of abnormally increased intraocular pressure, particularly those caused by glaucoma, by administration of phosphonylmethoxyalkyl nucleoside analogs are provided. Compositions formulated and packaged for intraocular administration for use in the methods are also provided. Administration of the compound may be by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or may be, when penetrating derivatives are used, by topical application to the eye. The degree of reduction in pressure is dosage-dependent, and significant reduction in pressure is obtained. A single injection can produce prolonged, and perhaps permanent, lowering of the intraocular pressure.
REFERENCES:
patent: 4230708 (1980-10-01), De Clercq et al.
patent: 4328803 (1982-05-01), Pape
patent: 4517925 (1985-05-01), Bracke et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4605658 (1986-08-01), Holy et al.
patent: 4724233 (1988-02-01), De Clercq et al.
patent: 4846172 (1989-07-01), Berlin
patent: 5039797 (1991-08-01), Clack et al.
patent: 5047533 (1991-09-01), Reist et al.
patent: 5116868 (1992-05-01), Chen et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5214080 (1993-05-01), Iwamura et al.
patent: 5229127 (1993-07-01), McKinzie
patent: 5273056 (1993-12-01), McLaughlin et al.
patent: 5273751 (1993-12-01), Dubroff
patent: 5278126 (1994-01-01), Katano et al.
patent: 5282851 (1994-02-01), Jacob-LaBarre
patent: 5292362 (1994-03-01), Bass et al.
patent: 5302585 (1994-04-01), Yu et al.
patent: 5468752 (1995-11-01), Freeman
patent: 5869468 (1999-02-01), Freeman
Banker et al., "Influence of intravitreal injecions of HPMPC and related nucleoside analogs on intraocular pressure of guinea pig eyes," Abstract, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, Apr. 1996.
Andrei, et al,. "Comparative Activity of Selected Antiviral Compounds against Clinical Isolates of Human Cytomegalovirus," Eur. J. Clin. Microbiol. Infect. Dis. 10(12):1026-1033 (1991).
Andreoli, et al., editors, Cecil Essentials of Medicine W.B. Saunders Company, publishers, pp. 690-691 (1986).
Assil and Weinreb, "Multivesicular Liposomes--Sustained Release of the Antimetabolite Cytarabine in the Eye," Arch. Ophthalmol. 105:400-403 (1987).
Berthe, et al., "Toxicologic and Pharmacokinetic Analysis of Intravitreal Injections of Foscarnet, Either Alone or in Combination With Ganciclovir," Invest. Ophthal. & Visual Sci. 35(3);1038-1045 (1994).
Cantrill, et al., "Treatment of Cytomegalovirus Retinitis with Intravitreal Ganciclovir," Ophthalmology 96(3):367-374 (1989).
Chemical Abstract 119:151515, Antivirals for the treatment of herpesvirus infections. DeClercq, Erik, J. Antimicrob. Chemother., 32(Supple. A), 121-32 (English) 1993.
De Clercq, "Broad-Spectrum Anti-DNA Virus and Anti-Retrovirus Activity of Phosphonylmethoxyalkylpurines and -Pyrimidines," Biochem. Pharm. 42(5):963-972 (1991).
De Clercq, Erik, "Antivirals for the treatment of herpesvirus infections," J. Antimicrobial Chemotherapy 32(A):121-132 (1993).
Diaz-Llopis, et al., "Intravitreal Foscarnet for Cytomegalovirus Retinitis in a Patient With Acquired Immunodeficiency Syndrome," American J. of Ophthalmology 115(5):686-688 (1993).
Dolnak, et al., "Lack of Retinal Toxicity of the Anticytomegalovirus Drug (S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine," Investigative Ophthalmology & Visual Science 33(5):1557-1563 (Apr. 1992).
Flores-Aquilar, et al., "Long-Acting Therapy of Viral Retinitis with (S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl)cytosine," J. of Infec. Diseases 69(3):642-647 (Mar. 1994).
Freeman, et al., "HPMPC for the Long Acting Treatment of Experimental Herpes Simplex Retinitis in Rabbits," 292:11:30 (Abstract), Investigative Ophthalmology & Visual Science, Annual Meeting Abstract Issue, May 3-8, 1992, Sarasota, FL.
Freeman, "Intraocular Antiviral Therapy," Arch. Ophthalmol. 107:1737-1739 (1989).
Friberg and Paul, "CMV Retinitis and Immunosuppression with FK506," Retina/Anatomy & Pathology/Clinical Res./Immunology & Microbiology Paper Presentation 291:11:15 (Abstract), Investigative Ophthalmology & Visual Science, Annual Meeting Abstract Issue, May 3-8, 1992, Sarasota, FL.
Gross, et al., "Longitudinal Study of Cytomegalovirus Retinitis in Acquired Immune Deficiency Syndrome," Ophthalmology 97:681-686 (1990).
Henderly, et al., "Cytomegalovirus Retinitis and Response to Therapy With Ganciclovir," Opthalmology 94(4):425-434 (1987).
Henry, et al., "Use of Intravitreal Ganciclovir (Dihydroxy Propoxymethyl Guanine) for Cytomegalovirus Retinitis in a Patient With Aids," Am. J. Ophthal. 103(1):17-23 (1987).
IUPAC-IUB Commission on Biochemical Nomenclature Symbols for Amino-Acid Derivatives and peptides Recommendations (1971), Biochemistry 11(9):17261732 (1972).
Jab, "Treatment of Cytomegalovirus Retinitis--1992," Arch. Ophthalmol. 110:185-187 (1992).
Kim, et al., "Preparation of Multivesicular Liposomes," Biochimica et Biophysica Acta 728:339-348 (1983).
Leibrandt, editor, Professional Guide to Disease, pp. 1203-1206 (1982).
Li, et al., "Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs," Antiviral Research 13:237-252 (1990).
Maudgal and De Clercq, "(S)-1(-3-Hydroxy-2-Phosphonyl-Methoxypropyl)Cytosine in the Therapy of Thymidine Kinase-Positive and -Deficient Herpes Simplex Virus Experimental Keratitis," Investigative Ophthalmol. & Visual Sci. 32(6):1816-1820 (1991).
Maudgal, et al., "Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK.sup.+ and TK.sup.- HSV-1 keratitis in rabbits," Antiviral Research 16(1):93-100 (Jul. 1991).
Neyts, et al., "Efficacy of (S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine and 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine for the Treatment of Murine Cytomegalovirus Infection in Severe Combined Immunodeficiency Mice," J. Med. Virol. 37:67-71 (1992).
Neyts, et al., "Selective Inhibition of Human Cytomegalovirus DNA Synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine ([(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG)," Virology 179:41-50 (1990).
Nogrady, "Medicinal Chemistry: A Biochemical Approach," Oxford Univ. Press, N.Y., pp. 388-392 (1985).
Sarraf, et al., "Transsceleral Iontophoresis of Foscarnet," American J. of Ophthalmology 115:748-754 (1993).
Sanborn, et al., "Sustained-Release Ganciclovir Therapy for Treatment of Cytomegalovirus Retinitis," Arch. Ophthalmol. 110:188-195 (1992).
Shigeta, et al., "Comparative Inhibitory Effects of Nucleoside Analogues on Different Clinical Isolates of Human Cytomegalovirus in Vitro," J. of Infectious Diseases 163:270-275 (1991).
Smith, et al., "Intravitreal Sustained-Release Ganciclovir," Arch. Ophthalmol. 110:255-258 (1992).
Ussery, et al., "Intravitreal Ganciclovir in the Treatment of AIDS-associated Cytomegalovirus Retinitis," Ophthalmology 95(5):640-648 (1988).
Fay Zohreh
Freeman William
Seidman Stephanie L.
LandOfFree
Treatment of conditions of abnormally increased intraocular pres does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of conditions of abnormally increased intraocular pres, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of conditions of abnormally increased intraocular pres will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1065233